Abstract 1406P
Background
Osimertinib is a standard first line treatment for advanced EGFR mutant lung cancer. While EGFR tyrosine kinase inhibitors are generally well tolerated, side effects, including diarrhea and rash, are common and often require dose modifications. The impact of osimertinib dose modification on survival outcomes is not known.
Methods
Patients with metastatic EGFR mutant lung cancer who received first line osimertinib between 2020 and 2022 were retrospectively identified using pharmacy records in British Columbia, Canada. Patient charts were reviewed to determine the incidence of dose reductions or treatment cessation of osimertinib due to toxicity. The type of toxicity leading to the treatment modification was also recorded. The median time to treatment discontinuation (mTTD) and the median overall survival (mOS) of patients requiring dose modification was compared to those who did not require modification using Kaplan Meier analysis and log rank testing.
Results
The analysis identified 311 patients and with a median follow up time of 26 months. 72 (23%) patients required a dose modification due to toxicity. At time of analysis, 52/72 (72%) of the dose modification group had stopped osimertinib vs 142/239 (60%) in the no modification group. The most frequent toxicities leading to dose reduction or cessation included diarrhea (17), skin toxicity (13), respiratory symptoms (10), anorexia (9), and cardiotoxicity (6). Pneumonitis occurred in 9 patients (3% of the study population). Twenty patients ultimately discontinued osimertinib due to toxicity. The mTTD was shorter in the dose reduction group, 14.3 months (95%CI 11.0-21.3) vs 21.9 months (95%CI 16.9-24.5) in the no reduction group (p=0.042). Second line treatment was received by 19/52 (35%) in the dose modification group and 59/145 (42%) in the no modification group. The mOS of patients requiring dose modifications was 27.6 months (95% CI 21.1-34.1), which was similar to patients not requiring dose modifications, mOS 26.8 months (95% CI 21.9-33.1), p=0.868.
Conclusions
Nearly one quarter of patients treated with osimertinib required a dose reduction or treatment cessation. Despite this, dose modifications did not lead to worse mOS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Ho: Financial Interests, Personal, Speaker, Consultant, Advisor: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Takeda. B. Melosky: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca Canada, Bristol Myers Squibb, Roche, Pfizer, Johnson and Johnson, Novartis, Amgen. J. Laskin: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche Canada, Pfizer, Jazz, AstraZeneca. Y. Wang: Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Merck, AstraZeneca. S. Sun: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20